Zhenlong Shao

478 total citations
16 papers, 363 citations indexed

About

Zhenlong Shao is a scholar working on Molecular Biology, Cell Biology and Cancer Research. According to data from OpenAlex, Zhenlong Shao has authored 16 papers receiving a total of 363 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 4 papers in Cell Biology and 4 papers in Cancer Research. Recurrent topics in Zhenlong Shao's work include Ubiquitin and proteasome pathways (9 papers), Histone Deacetylase Inhibitors Research (4 papers) and Protein Degradation and Inhibitors (4 papers). Zhenlong Shao is often cited by papers focused on Ubiquitin and proteasome pathways (9 papers), Histone Deacetylase Inhibitors Research (4 papers) and Protein Degradation and Inhibitors (4 papers). Zhenlong Shao collaborates with scholars based in China and United States. Zhenlong Shao's co-authors include Yuning Liao, Hongbiao Huang, Xiaohong Xia, Jinchan He, Yuan Liu, Lili Jiang, Chuyi Huang, Jinbao Liu, Cuifu Yu and Daolin Tang and has published in prestigious journals such as Oncogene, European Journal of Pharmacology and Cancer Letters.

In The Last Decade

Zhenlong Shao

15 papers receiving 362 citations

Peers

Zhenlong Shao

ONCOL

PRM

Jinchan He China

Tahir Sheikh United States

Cuifu Yu China

Marco Mazzoletti Italy

Rachel K. Toth United States

Chung‐Min Yeh Taiwan

Quanfu Huang China

Benjamin R. Topacio United States

Sahar Mazhar United States

Quyen Thu Bui South Korea

Jinchan He China

Zhenlong Shao

295 ×1.0

108 ×0.8

ONCOL

44 ×0.7

PRM

62 ×1.2

33 ×0.7

Citations per year, relative to Zhenlong Shao Zhenlong Shao (= 1×) peers Jinchan He

Countries citing papers authored by Zhenlong Shao

Since Specialization

Citations

This map shows the geographic impact of Zhenlong Shao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhenlong Shao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhenlong Shao more than expected).

Fields of papers citing papers by Zhenlong Shao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhenlong Shao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhenlong Shao. The network helps show where Zhenlong Shao may publish in the future.

Co-authorship network of co-authors of Zhenlong Shao

This figure shows the co-authorship network connecting the top 25 collaborators of Zhenlong Shao. A scholar is included among the top collaborators of Zhenlong Shao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhenlong Shao. Zhenlong Shao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Huang, Hongbiao, et al.. (2025). WBP11 inhibits UFL1-mediated UFMylation of NONO to drive hepatocellular carcinoma progression. Oncogene. 44(48). 4673–4685.

Huang, Hongbiao, Yuting Li, Qing Liu, et al.. (2024). The Ku70-SIX1-GPT2 axis regulates alpha-ketoglutarate metabolism to drive progression of prostate cancer. Oncogene. 44(2). 92–104. 2 indexed citations

Shao, Zhenlong, Shutong Liu, Xiaohong Xia, et al.. (2024). SENP3 mediates deSUMOylation of SIX1 to promote prostate cancer proliferation and migration. Cellular & Molecular Biology Letters. 29(1). 146–146. 3 indexed citations

Liu, Yuan, Cuifu Yu, Zhenlong Shao, et al.. (2022). SNS-023 sensitizes hepatocellular carcinoma to sorafenib by inducing degradation of cancer drivers SIX1 and RPS16. Acta Pharmacologica Sinica. 44(4). 853–864. 20 indexed citations

Liao, Yuning, Zhenlong Shao, Yuan Liu, et al.. (2022). A SIX1 degradation inducer blocks excessive proliferation of prostate cancer. International Journal of Biological Sciences. 18(6). 2439–2451. 17 indexed citations

Xia, Xiaohong, Chuyi Huang, Yuning Liao, et al.. (2021). The deubiquitinating enzyme USP15 stabilizes ERα and promotes breast cancer progression. Cell Death and Disease. 12(4). 329–329. 31 indexed citations

Wen, Xizhi, Leyi Yao, Zhenlong Shao, et al.. (2021). Bilirubin Restrains the Anticancer Effect of Vemurafenib on BRAF-Mutant Melanoma Cells Through ERK-MNK1 Signaling. Frontiers in Oncology. 11. 698888–698888. 3 indexed citations

Liao, Yuning, Zhenlong Shao, Yuan Liu, et al.. (2021). USP1-dependent RPS16 protein stability drives growth and metastasis of human hepatocellular carcinoma cells. Journal of Experimental & Clinical Cancer Research. 40(1). 201–201. 39 indexed citations

Liu, Yuan, Cuifu Yu, Zhenlong Shao, et al.. (2021). Selective degradation of AR-V7 to overcome castration resistance of prostate cancer. Cell Death and Disease. 12(10). 857–857. 34 indexed citations

10.

Liao, Yuning, Yuan Liu, Zhenlong Shao, et al.. (2021). A new role of GRP75-USP1-SIX1 protein complex in driving prostate cancer progression and castration resistance. Oncogene. 40(25). 4291–4306. 31 indexed citations

11.

Liao, Yuning, Yuan Liu, Xiaohong Xia, et al.. (2020). Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy. Theranostics. 10(8). 3366–3381. 58 indexed citations

12.

Liu, Yuan, Zhenlong Shao, Yuning Liao, et al.. (2020). Targeting SKP2/Bcr-Abl pathway with Diosmetin suppresses chronic myeloid leukemia proliferation. European Journal of Pharmacology. 883. 173366–173366. 16 indexed citations

13.

Xia, Xiaohong, Jinchan He, Qiong Xu, et al.. (2020). USP10 deletion inhibits macrophage-derived foam cell formation and cellular-oxidized low density lipoprotein uptake by promoting the degradation of CD36. Aging. 12(22). 22892–22905. 15 indexed citations

14.

Xia, Xiaohong, Jinchan He, Bin Liu, et al.. (2020). Targeting ERα degradation by L-Tetrahydropalmatine provides a novel strategy for breast cancer treatment. International Journal of Biological Sciences. 16(12). 2192–2204. 11 indexed citations

15.

Huang, Chuyi, Xiaohong Xia, Jinchan He, et al.. (2020). ERα is a target for butein-induced growth suppression in breast cancer.. PubMed. 10(11). 3721–3736. 7 indexed citations

16.

Xia, Xiaohong, Yuning Liao, Chuyi Huang, et al.. (2019). Deubiquitination and stabilization of estrogen receptor α by ubiquitin-specific protease 7 promotes breast tumorigenesis. Cancer Letters. 465. 118–128. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact